Basilea Pharmaceutica AG
BPMUF
$67.75
$6.4110.45%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 9,803.52% | 1,488.24% | 725.50% | 24.41% | -101.43% |
| Total Depreciation and Amortization | 5.76% | 3.47% | 3.41% | 27.59% | 66.20% |
| Total Amortization of Deferred Charges | -37.37% | -44.04% | -47.46% | -6.27% | 81.72% |
| Total Other Non-Cash Items | 135.28% | -74.51% | -536.61% | -438.17% | -352.04% |
| Change in Net Operating Assets | -103.29% | -49.77% | 260.22% | 159.96% | 147.80% |
| Cash from Operations | 693.39% | 534.32% | 452.87% | 108.52% | -62.94% |
| Capital Expenditure | -65.13% | -85.16% | -114.76% | -7.94% | 43.08% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -100.00% | -3.31% | -- | -- | -- |
| Other Investing Activities | 37.07% | 51.79% | 62.43% | -100.32% | -100.23% |
| Cash from Investing | -345.42% | -94.06% | -0.87% | -101.68% | -100.45% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | 86.53% | 73.69% | 7.27% | -206.52% |
| Issuance of Common Stock | -80.54% | -46.69% | -0.85% | -31.37% | -43.99% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -6,317.80% | -2,042.23% | 95.55% | 99.78% | 99.80% |
| Cash from Financing | 72.05% | 75.46% | 76.94% | 39.01% | -2.78% |
| Foreign Exchange rate Adjustments | -132.66% | 86.71% | 132.22% | 102.23% | 95.22% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -220.00% | -209.09% |
| Net Change in Cash | 247.77% | 242.32% | 237.51% | 9.08% | -171.51% |